Marisa Wexler, MS, senior science writer —

A $12.8 million five-year renewal grant from the National Institutes of Health (NIH) will fund research that seeks to better understand the molecular mechanisms that drive chronic obstructive pulmonary disease (COPD) and other lung diseases. The research also aims to increase understanding of how cigarette smoking affects the development…

Treatment with PRP-PC, an investigational platelet-based cellular therapy, may slow the decline in lung function typically experienced by people with chronic obstructive pulmonary disease (COPD), a new study with real-world data indicates. With this therapy, being developed by H-CYTE, a person’s own blood is treated in the lab…

The Zephyr Endobronchial Valve significantly improved lung function and quality of life for at least two years in people with emphysema, a severe form of chronic obstructive pulmonary disease (COPD), according to new clinical trial data. “These long-term data further demonstrate that our Zephyr Valve is a safe,…

Enrollment is now concluded in a clinical trial evaluating the mechanism of action of RejuvenAir Metered Cryospray, an investigational treatment for chronic bronchitis, the most common form of chronic obstructive pulmonary disease (COPD). Chronic bronchitis is long-term inflammation of the airways, characterized by coughing and excessive mucus production.

Smiths Medical has launched a medical device designed to help people with chronic obstructive pulmonary disease (COPD) and other respiratory diseases to clear secretions from their lungs and breathe better. “The introduction of the acapella choice blue therapy system enhances the quality of life for those living with…

Lannett is seeking the approval of a generic form of Advair Diskus (fluticasone-salmeterol powder) in the U.S. Such an approval would be expected to provide a less-expensive alternative to the inhalation treatment that generated about $3 billion in total U.S. sales for the 12 months ending in February 2021,…

Weight loss and a low body mass index (BMI) are associated with worse mortality outcomes among men with chronic obstructive pulmonary disease (COPD) in Japan, according to a new study. The study, “Low BMI and weight loss aggravate COPD mortality in men, findings from a large…

The Scottish Medicines Consortium (SMC) has approved AstraZeneca‘s triple combination therapy Trixeo Aerosphere as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The approval specifically covers adults with moderate to severe disease who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a…

The U.S. Food and Drug Administration (FDA) has granted Organicell Regenerative Medicine permission to begin a clinical trial testing the company’s lead product, Zofin, in people with chronic obstructive pulmonary disease (COPD). The approved trial design will be a double-blinded, placebo-controlled, phase 1/2 trial to assess the…

In people with chronic obstructive pulmonary disease (COPD) who experience acute exacerbations, the use of amoxicillin alone is associated with better outcomes than treatment with amoxicillin in combination with clavulanic acid, another antibiotic, a Danish study shows. The study, “Antibiotic treatment in acute exacerbation of COPD:…